Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aethlon Medical ( (AEMD) ) has provided an update.
On September 12, 2025, Aethlon Medical, Inc. announced that following a recent financing through a best-efforts public offering, the company has 7,373,156 outstanding shares. This development may impact the company’s financial structure and market positioning, potentially influencing stakeholder perceptions and future investment opportunities.
The most recent analyst rating on (AEMD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.
Spark’s Take on AEMD Stock
According to Spark, TipRanks’ AI Analyst, AEMD is a Underperform.
Aethlon Medical’s overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock’s outlook.
To see Spark’s full report on AEMD stock, click here.
More about Aethlon Medical
Average Trading Volume: 3,128,171
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.05M
See more insights into AEMD stock on TipRanks’ Stock Analysis page.